New daily pill shows promise for weight loss in early trial
NCT ID NCT07002905
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase IIa study tested a daily pill called ASC30 in 125 adults with obesity or overweight who also had weight-related health problems. The goal was to see if the drug helps with weight loss and is safe. Participants received either ASC30 or a placebo for up to 13 weeks, and researchers measured changes in body weight, waist size, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASC30 tablets
What this could lead to
If successful, this could lead to a new daily pill for weight loss in people with obesity or overweight.
What could go wrong
This is an early Phase IIa trial with only 125 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascletis Clinical Site
Rogers, Arkansas, 72758, United States
-
Ascletis Clinical Site
Fort Myers, Florida, 33912, United States
-
Ascletis Clinical Site
Miami, Florida, 33172, United States
-
Ascletis Clinical Site
Columbus, Ohio, 43212, United States
-
Ascletis Clinical Site
Bellaire, Texas, 77401, United States
-
Ascletis Clinical Site
San Antonio, Texas, 78240, United States